The Suprachoroidal Space: Exploring a New Age in the Treatment of Uveitic Macular Edema (CME Symposium)
This case-based, interactive symposium will cover the role of the suprachoroidal space as a delivery target in the treatment of retinal disease, relevant data on suprachoroidal injection of triamcinolone acetonide for the treatment of uveitic macular edema, and an injection technique used to deliver triamcinolone acetonide into the suprachoroidal space for the treatment uveitic macular edema.
This educational activity is intended for ophthalmologists.
After completing this activity, participants will be better able to:
- Describe the role of the suprachoroidal space as a delivery target in the treatment of retinal diseases
- Discuss the clinically relevant data of triamcinolone acetonide for the treatment of uveitic macular edema
- Apply the appropriate injection technique to deliver triamcinolone acetonide into the suprachoroidal space for the treatment of uveitic macular edema
- Use evidence-based approaches for local treatment of macular edema associated with uveitis
|Quan Dong Nguyen, MD, MSc (Chair)|
Professor of Ophthalmology, Professor of Pediatrics, and Professor of Medicine (Immunology/Rheumatology)
Byers Eye Institute
Stanford University School of Medicine
Palo Alto, California
|Peter K. Kaiser, MD|
Chaney Family Endowed Chair in Ophthalmology Research
Professor of Ophthalmology
Cole Eye Institute
Cleveland Clinic Lerner College of Medicine
|Rahul N. Khurana, MD|
Associate Clinical Professor of Ophthalmology
University of California, San Francisco
Northern California Retina Vitreous Associates
Mountain View, California
|Michael Singer, MD|
Clinical Professor of Ophthalmology
University of Texas Health Science Center
Director of Clinical Research
Medical Center Ophthalmology Associates
San Antonio, Texas
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Peter K. Kaiser, MD, is a consultant for Aerie Pharmaceuticals, Inc, AffaMed Therapeutics, AGTS, Allegro Ophthalmics, LLC, Allergan, Allgenesis Biotherapeutics Inc, Alnylam Pharmaceuticals, Inc, Alzheon, Inc, Annexon, Inc, AsclepiX Therapeutics, Aviceda Therapeutics, Bayer Corporation, Bausch & Lomb Incorporated, Biogen Idec, Bionic Vision Technologies, Boehringer Ingelheim International GmbH, Carl Zeiss Meditec, Inc, Chengdu Kanghong Pharmaceutical Group Co Ltd, Clearside Biomedical, Inc, Coherus Biosciences, Complement Therapeutics, DelSiTech Ltd, Dompé US, Inc, DTx Pharma, Eyevensys, Galimedix Therapeutics, Inc, Glaukos Corporation, Innovent Biologics, Inc, iRenix Medical, Inc, Iveric Bio, Inc, jCyte, Kanaph Therapeutics, Kera Therapeutics, Inc, Kodiak Sciences Inc, Kriya Therapeutics, LensGen, Nanoscope Therapeutics, Inc, Novartis Pharmaceuticals Corporation, Ocugenix, Ocular Therapeutics, Oculis, Ocuphire Pharma, OcuTerra Therapeutics, Omeros Corporation, Oxurion NV, Palatin, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, Retina AI Inc, Retinal Sciences, Roivant Sciences Ltd, Samsung Bioepis, SGN Nanopharma Inc, Stealth BioTherapeutics Inc, Stuart Therapeutics, Sustained Nano Systems, LLC, Takeda Pharmaceuticals USA, Inc, Thea Pharmaceuticals Limited, and Unity Biotechnology.
Rahul N. Khurana, MD, is an advisory board member of Apellis Pharmaceuticals, Bausch & Lomb Incorporated, Genentech, Inc, NGM Biopharmaceuticals, and Opthea; and is a contracted researcher for Apellis Pharmaceuticals, Chengdu Kanghong Pharmaceutical Group Co Ltd, Clearside Biomedical, Inc, EyePoint Pharmaceuticals, Genentech, Inc, NGM Biopharmaceuticals, Opthea, Oxurion NV, and Regenexbio Inc.
Quan Dong Nguyen, MD, MSc, is an advisory board member of Bausch & Lomb Incorporated, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals, Inc.
Michael Singer, MD, is a consultant for Allergan, EyePoint Pharmaceuticals, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals, Inc; and is on the speakers bureau for Allergan, Apellis Pharmaceuticals, Bausch & Lomb Incorporated, EyePoint Pharmaceuticals, Genentech, Inc, Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals, Inc.
Christopher Henry, MD, is a consultant for Bausch & Lomb Incorporated and Clearside Biomedical, Inc; and is also an advisory board member of Alimera Sciences, Allergan, Bausch & Lomb Incorporated, and EyePoint Pharmaceuticals.
Gennady Landa, MD, formerly served as an advisory board member of EyePoint Pharmaceuticals within the past 2 years, but that relationship has ended.
Planners, Managers, and Writers
Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS within the past 2 years, but that relationship has ended.
Other MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Bausch & Lomb Incorporated.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Bausch & Lomb Incorporated.
©2022 MedEdicus LLC. 280.1
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation